Adamas Pharmaceuticals Inc (NASDAQ:ADMS) – Analysts at Piper Jaffray Companies reduced their FY2021 EPS estimates for shares of Adamas Pharmaceuticals in a research note issued to investors on Thursday, November 1st. Piper Jaffray Companies analyst D. Amsellem now anticipates that the specialty pharmaceutical company will earn $0.30 per share for the year, down from their prior forecast of $0.35. Piper Jaffray Companies also issued estimates for Adamas Pharmaceuticals’ FY2022 earnings at $2.05 EPS.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.34) by $0.12. The business had revenue of $10.61 million during the quarter, compared to the consensus estimate of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 104.27% and a negative net margin of 617.27%.
Several other brokerages have also recently issued reports on ADMS. HC Wainwright set a $45.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 6th. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 17th. Leerink Swann restated an “outperform” rating on shares of Adamas Pharmaceuticals in a research report on Friday, October 19th. ValuEngine cut Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 28th. Finally, Mizuho restated a “buy” rating and issued a $75.00 price target on shares of Adamas Pharmaceuticals in a research report on Friday, August 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. Adamas Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $42.00.
Shares of ADMS stock opened at $11.89 on Monday. The stock has a market capitalization of $323.29 million, a P/E ratio of -2.99 and a beta of 1.53. Adamas Pharmaceuticals has a 52-week low of $11.70 and a 52-week high of $44.00. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.74 and a current ratio of 9.92.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMS. Wells Fargo & Company MN lifted its stake in Adamas Pharmaceuticals by 7.5% in the 1st quarter. Wells Fargo & Company MN now owns 44,138 shares of the specialty pharmaceutical company’s stock valued at $1,055,000 after buying an additional 3,090 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Adamas Pharmaceuticals by 15.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 35,490 shares of the specialty pharmaceutical company’s stock worth $849,000 after acquiring an additional 4,800 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Adamas Pharmaceuticals by 12.7% in the first quarter. Northern Trust Corp now owns 223,055 shares of the specialty pharmaceutical company’s stock worth $5,330,000 after acquiring an additional 25,167 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Adamas Pharmaceuticals by 10.4% in the first quarter. BlackRock Inc. now owns 1,484,793 shares of the specialty pharmaceutical company’s stock worth $35,486,000 after acquiring an additional 139,385 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Adamas Pharmaceuticals by 49.8% in the first quarter. Sei Investments Co. now owns 7,627 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 2,536 shares during the last quarter. Institutional investors and hedge funds own 95.23% of the company’s stock.
In other Adamas Pharmaceuticals news, CFO Alfred G. Merriweather sold 1,665 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $19.18, for a total transaction of $31,934.70. Following the transaction, the chief financial officer now owns 25,460 shares in the company, valued at approximately $488,322.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 24.60% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.